For a decade, UnicoCell pioneered stem cell therapy R&D. UnicoCell's Gold Award-winning new stem cell product, ELIXCYTE®, has advanced to the case enrollment phase of Phase III clinical trials for knee osteoarthritis and has reached the unblinding process of Phase II clinical trials for chronic kidney disease, promising innovative treatments for aging-related diseases. The company follows ICH guidelines, holds a 2022 US FDA Master File (MF) for an adipose-derived stem cell bank, a vital raw material for stem cell drug development. UnicoCell has innovated two patented products: 1. Stem Cell Secretome, which is FDA MF-recognized, and is applied for degenerative eye diseases, regenerative medicine, and exosome research. 2. UnicoVial® ultra-low temperature storage, obtained TFDA Class II medical device approval and FDA MF-recognized, applied for cell therapy and biological product storage. UnicoCell aspires to globalize stem cell technology, promote regenerative medicine for aging-related conditions, and ultimately enhance the quality of human life.